Pretty much as expected, with action taken to reduce costs and increase focus in realising the potential growth in business of the SIR-Spheres Y-90 . The reason for the annual loss in profit is the $90.5 million one off clinical & R&D asset impairment and restructuring cost.
I reckon the market will react positively to this result and we will see slow movement up in the SP during the next 12 months.
Ann: Sirtex Records Underlying Full Year NPAT of $42.4 Million, page-2
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $77.74M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.3¢ | 18.0¢ | $131.8K | 732.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 36255134 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 4525798 | 22 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |